Quinidine in the treatment of KCNT1-positive epilepsies

Annals of Neurology

Volumn 78, Issue 6, 2015, Pages 995-999

  Mikati, Mohamad A ^a   Jiang, Yong Hui ^a   Carboni, Michael ^a   Shashi, Vandana ^a   Petrovski, Slave ^a   Spillmann, Rebecca ^a   Milligan, Carol J ^b   Li, Melody ^b   Grefe, Annette ^c   McConkie, Allyn ^a   Berkovic, Samuel ^b   Scheffer, Ingrid ^b   Mullen, Saul ^b   Bonner, Melanie ^a   Petrou, Steven ^b   Goldstein, David ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOBARBITAL; QUINIDINE; ENZYME INHIBITOR; KCNT1 PROTEIN, HUMAN; NERVE PROTEIN; POTASSIUM CHANNEL;

ANTICONVULSANT THERAPY; ARTICLE; CASE REPORT; CHILD; CHILD HOSPITALIZATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESISTANT EPILEPSY; ECG ABNORMALITY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; EXOME; FEMALE; FOCAL EPILEPSY; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; KCNT1 GENE; MALE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; QT INTERVAL; SCHOOL CHILD; TONIC CLONIC SEIZURE; GENETICS; MUTATION;

CHILD; CHILD, PRESCHOOL; DRUG RESISTANT EPILEPSY; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MUTATION; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS; QUINIDINE;

EID: 84943000123     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24520     Document Type: Article

References (18)

1. Derry CP, Heron SE, Phillips F, et al., Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disability. Epilepsia 2008: 49: 2125-2129.
2. Hern SE, Smith KR, Bahlo M, et al., Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012: 44: 1188-1190.
3. Coppola PP, Chiron C, Robain O, Dulac O,. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 1995: 36: 1017-1024.
4. Barcia G, Fleming MR, Deligniere A, et al., De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012: 44: 1255-1260.
5. Milligan CJ, Li M, Gazina EV, et al., KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014; 75: 581-590.
6. Bearden D, Strong A, Ehnot J, et al., Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014; 76: 457-461.
7. Marquez MF, Bonny A, Hernandez-Castillo E, et al., Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012; 9: 1995-2000.
8. Ochs HR, Greenblatt DJ, Lloyd BL, et al., Entry of quinidine into cerebrospinal fluid. Am Heart J 1980; 100: 341-346.
9. Westerhout J, Smeets J, Danhof M, de Lange EC,. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn 2013; 40: 327-342.
10. Gigout S, Louvel J, Kawasaki H, et al., Effects of gap junction blockers on human neocortical synchronization. Neurobiol Dis 2006; 22: 496-508.
11. Voss LJ, Jacobson G, Sleigh JW, et al., Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice. Epilepsia 2009; 50: 1971-1978.
12. Data JL, Wilkinson GR, Nies AS,. Interaction of quinidine with anticonvulsant drugs. N Engl J Med 1976; 294: 699-702.
13. Ngui JS, Chen Q, Shou M, et al., In-vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′3- and 10-hydroxywarfarin. Drug Metab Dispos 2001; 29: 877-886.
14. Ngui JS, Tang W, Stearns RA, et al., Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 2000; 28: 1043-1050.
15. Damkier P, Brøsen K,. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 2000; 68: 199-209.
16. von Moltke LL, Greenblatt DJ, Duan SX, et al., Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in-vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998; 87: 1184-1189.
17. + channel determined by construction of multimeric cDNAs. Neuron 1992; 9: 861-871.
18. Petrou S, Ugur M, Drummond RM, et al., P2X7 purinoceptor expression in Xenopus oocytes is not sufficient to produce a pore-forming P2Z-like phenotype. FEBS Lett 1997; 411: 339-345.